Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

Leukemia

Volumn 27, Issue 4, 2013, Pages 977-980

  Sokol, L ^a   Cripe, L ^b   Kantarjian, H ^c   Sekeres, M A ^d   Parmar, S ^e   Greenberg, P ^f   Goldberg, S L ^g   Bhushan, V ^h   Shammo, J ⁱ   Hohl, R ^j   Verma, A ^k   Garcia Manero, G ^c   Li, Y P ^l   Lowe, A ^l   Zhu, J ^l   List, A F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF IOWA   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l SCIOS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TALMAPIMOD;

ABDOMINAL PAIN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; CANCER GROWTH; CHEST TIGHTNESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DUODENUM ULCER; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; JAUNDICE; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 14; MYELODYSPLASTIC SYNDROMES; PROTEIN KINASE INHIBITORS;

EID: 84876114118     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.264     Document Type: Letter

References (10)

1. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2004; 297-317.
2. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signaling. Biochem J 2010; 429: 403-417.
3. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 2002; 168: 5984-5988.
4. Katsoulidis E, Li Y, Yoon P, Sassano A, Altman J, Kannan-Thulasiraman P et al. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005; 65: 9029-9037.
5. Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006; 108: 4170-4177.
6. Nikas SN, Drosos AA. SCIO-469 Scios Inc. Curr Opin Investig Drugs 2005; 5: 1205-1212.
7. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
8. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
9. NCI Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep. cancer.gov/forms/CTCAEv3.pdf.
10. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 2000; 102: 221-231.